Document is current

Article History

Received: 24 April 2026

Accepted: 12 May 2026

First Online: 8 June 2026

Declarations

:

: This study consisted of a voluntary survey of clinicians and did not include any patient data or personal health information. As such, it did not require review by an institutional review board. The investigation was conducted in accordance with the principles of the World Medical Association Declaration of Helsinki: Research Involving Human Participants.

: Participants were informed of the purpose of the study, and completion of the survey was considered to indicate informed consent.

: No personally identifiable material was included in this report.

: L.N.G.C. has received honoraria from Elsevier, BMJ Best Practice, Oakstone Publishing, Prime Education and Servier, as well as research support from Merck & Co, Conquer Cancer (The ASCO Foundation), the Robert Wood Johnson Foundation, the Robert A. Winn Excellence in Clinical Trials Award Program, and the National Cancer Institute. H.K.P. reports consulting role: Novocure.R.E.S. reports grants or contract to his institution from the National Institutes of Health; personal royalites from Elsevier and Lecturio; consulting fees from Monteris Medical, Novocure, and SpringWorks Therapeutics; participation on a data safety monitoring board for tanezumab (Massachusetts General Hospital); editorial stipend from the American Academy of Neurology; and board membership of the Accreditation Council for Continuing Medical Education and the North Carolina Medical Society Foundation. M.T.M. reports honoraria; Wolters Kluwer. Section Editor; Int J Radiat Oncol Biol Phys. develop guidelines; American Radium Society.M.T.M. reports honoraria from Wolters Kluwer. Consulting/Advisory Role: Nuvation Bio, Deciphera, Telix, Servier, Alexion Pharmaceuticals, Inc. P.Y.W. reports grants or contracts from AstraZeneca, Black Diamond, Bristol Myers Squibb, Chimerix, the Global Coalition for Adaptive Research, Kazia, MediciNova, Merck, Nerviano, Novartis, Philogen, Quadriga, and Servier; consulting fees from Alexion/AstraZeneca, Bristol Myers Squibb, Chimerix, Day One Bio, ImVax, Fore Biotherapeutics, Genenta, GlaxoSmithKline, Merck, Nerviano, Nuvation Bio Medical Sciences, Novartis, Novocure, Rigel, Sapience, Servier, and Telix; payment or honoraria from Medscape, Med Learning, Peer Review CME, and Research to Practice.